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Fecal microbiota transplantation (FMT) has emerged as a highly effective treatment for Clostridium
difﬁcile infection (CDI), the most frequent cause of hospital-acquired infectious diarrhea in developed
countries and the cause of nearly 30,000 annual deaths in the US. FMT is proving to be more effective at
treating CDI than traditional antibacterial therapy, and reduces the exposure of valuable antibiotics to
potential resistance. A systematic review to assess the efﬁcacy of FMT for CDI treatment showed that
across all studies for recurrent CDI, symptom resolution was observed in 85% of patients. The United
States Food and Drug Administration currently classiﬁes FMT as an investigational drug, which imparts
overly restrictive regulations that are impossible to apply to FMT in the same manner as conventional
drugs. Reclassiﬁcation of FMT to a human cell, tissue, and cellular and tissue-based product could
potentially expand access to this important treatment while maintaining rigorous safety standards.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Fecal microbiota transplantation (FMT) is the transfer of stool
from a healthy donor to provide “good bacteria” as a therapeutic
agent and has emerged as a highly effective treatment for Clos-
tridium difﬁcile infections (CDIs). A recently published systematic
review on the use of FMT to treat CDI showed that across all studies,
85% of patients with recurrent CDI treated with FMT achieved the
resolution of symptoms [1]. FMT avoids problems associated with
antibiotic use, including high cost, low efﬁcacy, and the potential
for recurrence and resistance. Notwithstanding the exceptional
results among patients receiving FMT, the United States Food and
Drug Administration (FDA) has legitimate concerns about the efﬁ-
cacy and safety proﬁle of this treatment, particularly its long-term
effects, and classiﬁes FMT as an investigational drug. The encum-
bering regulations that accompany the investigational drug classi-
ﬁcation are impractical for applying to FMT in the same manner as
conventional drugs. Reclassifying FMT to a human cell, tissue, andon (FMT) has emerged as a
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Inc. This is an open access article ucellular and tissue-based product (HCT/P) could potentially allow
greater numbers of patients to beneﬁt from this effective treat-
ment, while still maintaining the rigorous safety standards required
for any human tissue intended for transplantation.1. Clostridium difﬁcile
CDI is the most frequent cause of hospital-acquired infectious
diarrhea in developed countries [2] and accounts for 20e30% of all
cases of antibiotic-associated diarrhea [3]. The hospitalization rate
for CDI in the United States more than doubled from 2001 to 2011
[4], resulting in an estimated 453,000 incident CDIs and 29,300
deaths in 2011 [5].
CDI also creates signiﬁcant ﬁnancial costs. The cost of CDI
treatment ranges from $3006 [6] to as high as $15,397 per patient
[7]. The nationwide ﬁnancial burden due to C. difﬁcile is approxi-
mately $4.8 billion for acute care facilities alone [8].
The gut microbiota, the vast community of microorganisms in
the gastrointestinal tract, protects the body from invading patho-
gens by competing for resources. C. difﬁcile is an opportunistic
pathogen that has become a serious problem in health care settings
and is most commonly associated with hospitalized patients
receiving antibiotic therapies. The antibiotics these patients receive
can destroy the helpful bacteria and perturb the gut microbiota,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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colon and potentially allow bacteria to leak into the bloodstream,
resulting in septicemia.
Antibiotic usemay cause CDI, and, ironically, antibiotics are used
to treat the infection. The most effective antibacterial treatment for
CDI, vancomycin, is on the World Health Organization's List of
Essential Medicines and is also used to treat a variety of infections,
including potentially deadly methicillin-resistant Staphylococcus
aureus (MRSA) infections.
A key issue with vancomycin use for CDI treatment is the high
rate of recurrence following the initial treatment. In one double
blind, non-inferiority, randomized, controlled trial (RCT), the
recurrence rate in patients treated with vancomycin for the initial
CDI was 26.9% [9]. Recurrent CDI has recently become more com-
mon due (in part) to a new, hyper-virulent strain that is less
responsive to traditional antibiotic treatments. Recurrent CDI is also
associated with a signiﬁcantly increased risk of death compared
with that in CDI patients who do not develop recurrence [10,11].
2. Clinical efﬁcacy of FMT
A systematic review designed to assess the efﬁcacy, comparative
effectiveness, and adverse effects of FMT for CDI treatment revealed
that, across all studies for recurrent CDI, symptom resolution was
observed in 85% of patients [1]. This review identiﬁed two ran-
domized, controlled trials (RCTs) and 28 case-series studies
regarding the efﬁcacy of FMT for recurrent CDI, refractory CDI, or an
initial episode of CDI. Most studies involved recurrent CDIs. In one
RCT, 43 patients were randomly assigned to receive FMT, vanco-
mycin, or vancomycin and bowel lavage. 81% of FMT patients ach-
ieved resolution of symptoms within three months compared with
only 31% of patients who received vancomycin and 23% of patients
who received vancomycin and bowel lavage [12]. The interim re-
sults of this trial demonstrated that FMT was signiﬁcantly superior
to standard antibacterial therapy. The results were so profound that
the trial was terminated early in accordance with the Hay-
bittleePeto rule, which speciﬁes a p-value (often p < 0.001) for
stopping the trial early [13,14]. Overall, in the two RCTs, 75% of
patients receiving FMT experienced the resolution of symptoms
with no additional recurrence.
Interest in FMT is increasing, and the United States National
Institutes of Health lists three active clinical trials investigating the
use of FMT to treat CDI [15e17]. More than 40 additional trials are
recruiting patients.
3. Classiﬁcation and regulation of FMT
In 2012, the FDA classiﬁed FMT as an investigational drug. This
classiﬁcation requires an Investigational New Drug (IND) applica-
tion for use in humans. Assembling a single IND application can
take months or even years, and this time frame is unacceptable for
patients requiring treatment for CDI. Due to considerable opposi-
tion from clinicians, in July 2013, the FDA issued a statement and
declared a temporary enforcement of discretion when FMT is used
clinically to treat CDI. Thus, for CDI patients, physicians may pro-
ceed with FMT without navigating the time-consuming process of
ﬁling an IND. However, there is no guarantee that this guidelinewill
remain in place indeﬁnitely.
Despite the remarkable results among patients receiving FMT,
the FDA remains concerned about the efﬁcacy and safety proﬁle of
this treatment, especially regarding the long-term effects. The po-
tential challenges for deﬁning FMT are related to the active ingre-
dient, potency, stability, and manufacturing process. These
concerns are legitimate, and although these issues are valid for an
investigational drug, they should not impede the broad acceptanceand use of FMT.
The human stool used for FMT is a highly variable mixture of
inorganic and organic matter that inherently differs from a con-
ventional drug in the sense that everyone naturally produces it. The
current classiﬁcation of FMT as an investigational drug imparts
overly restrictive regulations, which are impossible to apply to FMT
in the same manner as conventional drugs since it does not origi-
nate from pharmaceutical factories, nor is it created in a laboratory
[18]. If the FDA reclassiﬁed FMT as a human cell, tissue, and cellular
and tissue-based product (HCT/P), then FMT would be regulated
under Title 21, Part 1270 and 1271 of the Code of Federal Regula-
tions regarding human tissue intended for transplantation. FMT
would then be regulated as other non-vascularized human tissue,
such as bone, skin, corneas, and ligaments.
The HCT/P classiﬁcation excludes products excreted from the
body. However, there is a precedent for the FDA tomake exceptions
to this rule because the FDA classiﬁes semen as human tissue. A
similar exception might be made for FMT. Reclassifying FMT as an
HCT/P could potentially expand access to care and alleviate re-
strictions on research while concurrently ensuring safety through
the same mandatory screening of samples and recordkeeping
required for any human tissue intended for transplantation.
Because FMT has a high cure rate in multiple trials with few
serious adverse events [1,12,19,20], the timely reclassiﬁcation of
FMT to an HCT/P would most likely cause increased use of FMT and
less antibiotic use.
Antibiotic resistance is a major hazard to public health and
threatens the advancement of modern medicine [21]. FMT is
proving to be more effective for treating CDI than traditional anti-
bacterial therapy, and FMT reduces the risk of valuable antibiotics
causing resistance. Therefore, the increased use of FMT would be
mutually beneﬁcial from both a patient and public health
perspective. The awareness of FMT among the general public is
increasing. However, the responsibility for increasing the use of
FMT rests with medical practitioners, regulatory bodies, and the
wider public health community. We argue that the public health
would be served by better access to this important treatment when
physicians deem it to be indicated, and the reclassiﬁcation of FMT
to an HCT/P is a potential avenue to increase this access.
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